Paxlovid Speeds COVID-19 Recovery in High-Risk Patients, New Trials Reveal

The role of Paxlovid in treating COVID-19 is shifting as new evidence emerges regarding its efficacy in vaccinated populations. According to results from two national trials published in The New England Journal of Medicine, the antiviral treatment does not reduce the incidence of death or hospitalization among high-risk patients who have been vaccinated against SARS-CoV-2 when compared with usual care.

The research involved two distinct national studies: the PANORAMIC trial conducted in the United Kingdom and the CanTreatCOVID trial conducted in Canada. Both trials focused on patients categorized as high-risk, yet found that the medication did not lower the risk of severe outcomes like hospitalization or death in those who had already received vaccinations.

Despite the lack of impact on hospitalization and mortality rates, experts noted that Paxlovid did speed up the recovery process in a meaningful way for these patients.

Paxlovid, produced by Pfizer, is a combination medication consisting of the antiviral regimen nirmatrelvir-ritonavir. While its primary utility has historically been linked to preventing the progression of the disease to severe stages, these findings suggest its clinical application is evolving.

The results indicate that for vaccinated individuals at high risk, the benefit of the treatment may be more closely tied to the speed of recovery rather than the prevention of the most severe clinical outcomes.